FABP5

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
FABP5
Protein FABP5 PDB 1b56.png
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesFABP5, E-FABP, EFABP, KFABP, PA-FABP, PAFABP, fatty acid binding protein 5
External IDsMGI: 101790 HomoloGene: 108238 GeneCards: FABP5
Gene location (Human)
Chromosome 8 (human)
Chr.Chromosome 8 (human)[1]
Chromosome 8 (human)
Genomic location for FABP5
Genomic location for FABP5
Band8q21.13Start81,280,363 bp[1]
End81,284,777 bp[1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001444

NM_001272097
NM_001272098
NM_010634

RefSeq (protein)

NP_001435

NP_001259026
NP_001259027
NP_034764

Location (UCSC)Chr 8: 81.28 – 81.28 MbChr 3: 10.01 – 10.02 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Fatty acid-binding protein, epidermal is a protein that in humans is encoded by the FABP5 gene.[5][6]

Function[edit]

This gene encodes the fatty acid binding protein found in epidermal cells, and was first identified as being upregulated in psoriasis tissue. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism.[6]

The phytocannabinoids (THC and CBD) inhibit endocannabinoid anandamide (AEA) uptake by targeting FABP5, and competition for FABPs may in part or wholly explain the increased circulating levels of endocannabinoids reported after consumption of cannabinoids.[7] Results show that cannabinoids inhibit keratinocyte proliferation, and therefore support a potential role for cannabinoids in the treatment of psoriasis.[8]

Interactions[edit]

FABP5 has been shown to interact with S100A7.[9][10]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000164687 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000027533 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Madsen P, Rasmussen HH, Leffers H, Honoré B, Celis JE (September 1992). "Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins". The Journal of Investigative Dermatology. 99 (3): 299–305. doi:10.1111/1523-1747.ep12616641. PMID 1512466. 
  6. ^ a b "Entrez Gene: FABP5 fatty acid binding protein 5 (psoriasis-associated)". 
  7. ^ Elmes MW, Kaczocha M, Berger WT, Leung K, Ralph BP, Wang L, Sweeney JM, Miyauchi JT, Tsirka SE, Ojima I, Deutsch DG (April 2015). "Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)". The Journal of Biological Chemistry. 290 (14): 8711–21. doi:10.1074/jbc.M114.618447. PMC 4423662Freely accessible. PMID 25666611. 
  8. ^ Wilkinson JD, Williamson EM (February 2007). "Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis". Journal of Dermatological Science. 45 (2): 87–92. doi:10.1016/j.jdermsci.2006.10.009. PMID 17157480. 
  9. ^ Ruse M, Broome AM, Eckert RL (July 2003). "S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes". The Journal of Investigative Dermatology. 121 (1): 132–41. doi:10.1046/j.1523-1747.2003.12309.x. PMID 12839573. 
  10. ^ Hagens G, Roulin K, Hotz R, Saurat JH, Hellman U, Siegenthaler G (February 1999). "Probable interaction between S100A7 and E-FABP in the cytosol of human keratinocytes from psoriatic scales". Molecular and Cellular Biochemistry. 192 (1-2): 123–8. doi:10.1023/A:1006894909694. PMID 10331666. 

Further reading[edit]